Astellas Pharma Inc. (FRA:YPH)

Astellas Pharma Statistics

Total Valuation

Astellas Pharma has a market cap or net worth of EUR 19.55 billion. The enterprise value is 22.07 billion.

Market Cap	19.55B
Enterprise Value	22.07B

Important Dates

The next estimated earnings date is Tuesday, February 3, 2026.

Earnings Date	Feb 3, 2026
Ex-Dividend Date	Sep 29, 2025

Share Statistics

Current Share Class	1.79B
Shares Outstanding	n/a
Shares Change (YoY)	-0.07%
Shares Change (QoQ)	+0.14%
Owned by Insiders (%)	0.02%
Owned by Institutions (%)	53.32%
Float	1.79B

Valuation Ratios

The trailing PE ratio is 27.19.

PE Ratio	27.19
Forward PE	n/a
PS Ratio	1.69
PB Ratio	2.11
P/TBV Ratio	21.45
P/FCF Ratio	9.28
P/OCF Ratio	8.49
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.12, with an EV/FCF ratio of 10.47.

EV / Earnings	30.68
EV / Sales	1.98
EV / EBITDA	7.12
EV / EBIT	10.89
EV / FCF	10.47

Financial Position

The company has a current ratio of 1.03, with a Debt / Equity ratio of 0.46.

Current Ratio	1.03
Quick Ratio	0.76
Debt / Equity	0.46
Debt / EBITDA	1.32
Debt / FCF	2.02
Interest Coverage	28.40

Financial Efficiency

Return on equity (ROE) is 7.95% and return on invested capital (ROIC) is 9.58%.

Return on Equity (ROE)	7.95%
Return on Assets (ROA)	6.68%
Return on Invested Capital (ROIC)	9.58%
Return on Capital Employed (ROCE)	17.37%
Revenue Per Employee	847,151
Profits Per Employee	52,713
Employee Count	13,643
Asset Turnover	0.58
Inventory Turnover	1.32

Taxes

In the past 12 months, Astellas Pharma has paid 68.71 million in taxes.

Income Tax	68.71M
Effective Tax Rate	8.72%

Stock Price Statistics

The stock price has increased by +9.13% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+9.13%
50-Day Moving Average	9.44
200-Day Moving Average	8.82
Relative Strength Index (RSI)	61.60
Average Volume (20 Days)	639

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Astellas Pharma had revenue of EUR 11.56 billion and earned 719.16 million in profits. Earnings per share was 0.40.

Revenue	11.56B
Gross Profit	9.39B
Operating Income	2.13B
Pretax Income	787.87M
Net Income	719.16M
EBITDA	3.24B
EBIT	2.13B
Earnings Per Share (EPS)	0.40

Balance Sheet

The company has 1.65 billion in cash and 4.26 billion in debt, giving a net cash position of -2.61 billion.

Cash & Cash Equivalents	1.65B
Total Debt	4.26B
Net Cash	-2.61B
Net Cash Per Share	n/a
Equity (Book Value)	9.29B
Book Value Per Share	5.18
Working Capital	249.82M

Cash Flow

In the last 12 months, operating cash flow was 2.30 billion and capital expenditures -193.79 million, giving a free cash flow of 2.11 billion.

Operating Cash Flow	2.30B
Capital Expenditures	-193.79M
Free Cash Flow	2.11B
FCF Per Share	n/a

Margins

Gross margin is 81.28%, with operating and profit margins of 18.39% and 6.22%.

Gross Margin	81.28%
Operating Margin	18.39%
Pretax Margin	6.82%
Profit Margin	6.22%
EBITDA Margin	28.06%
EBIT Margin	18.39%
FCF Margin	18.24%

Dividends & Yields

This stock pays an annual dividend of 0.45, which amounts to a dividend yield of 4.29%.

Dividend Per Share	0.45
Dividend Yield	4.29%
Dividend Growth (YoY)	1.78%
Years of Dividend Growth	9
Payout Ratio	106.09%
Buyback Yield	0.07%
Shareholder Yield	4.36%
Earnings Yield	3.68%
FCF Yield	10.78%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on March 27, 2014. It was a forward split with a ratio of 5.

Last Split Date	Mar 27, 2014
Split Type	Forward
Split Ratio	5

Scores

Astellas Pharma has an Altman Z-Score of 2.17 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.17
Piotroski F-Score	6